Gilead Sciences, devletin stratejik yerli \u00fcretim \u00f6ncelikleri do\u011frultusunda en yenilik\u00e7i ve hayat kurtaran ila\u00e7lar\u0131n\u0131 T\u00fcrkiye\u2019de \u00fcretecek.<\/p>\n
Gilead Sciences, devletin stratejik yerli \u00fcretim \u00f6ncelikleri do\u011frultusunda en yenilik\u00e7i ve hayat kurtaran ila\u00e7lar\u0131n\u0131 T\u00fcrkiye\u2019de \u00fcretmek \u00fczere Pharmactive \u0130la\u00e7 ile \u00fcretim i\u015fbirli\u011fine gidiyor. T\u00fcrkiye, Gilead Sciences\u2019\u0131n ilgili ila\u00e7lar i\u00e7in halihaz\u0131rda \u00fcretim yapmakta oldu\u011fu Kanada ve \u0130rlanda\u2019dan sonra 3\u2019\u00fcnc\u00fc \u00fcretim \u00fcss\u00fc olacak. Yerli \u00fcretim i\u00e7in Pharmactive \u0130la\u00e7 ile i\u015fbirli\u011fi anla\u015fmas\u0131 imzalayan Gilead Sciences T\u00fcrkiye, b\u00f6ylece toplam cirosunun y\u00fczde 70\u2019inden fazlas\u0131n\u0131 T\u00fcrkiye\u2019de \u00fcretir duruma gelecek. Yerel \u00fcretime ili\u015fkin anla\u015fma, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 yetkililerinin de kat\u0131l\u0131m\u0131yla, Gilead Sciences T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc \u015eebnem Girgin ve Pharmactive \u0130la\u00e7 Y\u00f6netim Kurulu Ba\u015fkan\u0131 Haluk Sancak taraf\u0131ndan imzaland\u0131.<\/p>\n
Proje kapsam\u0131nda, D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc\u2019nce (DS\u00d6) ilaca eri\u015fimin en kritik oldu\u011fu hastal\u0131klar olarak tan\u0131mlanan hepatit ve HIV alanlar\u0131ndaki hayat kurtaran stratejik ila\u00e7lar, bundan b\u00f6yle T\u00fcrkiye\u2019de Pharmactive \u0130la\u00e7 i\u015fbirli\u011fiyle \u00fcretilecek. \u0130lk olarak d\u00fcnyada y\u0131ll\u0131k sat\u0131\u015f\u0131n\u0131n 1 milyar dolara ula\u015fmas\u0131 beklenen Hepatit B ilac\u0131 ile ba\u015flayacak olan projenin, d\u00fcnyada y\u0131ll\u0131k sat\u0131\u015f\u0131n\u0131n 8 ila 10 milyar dolar seviyesinde ger\u00e7ekle\u015fmesi beklenen, en son ke\u015ffedilen, yenilik\u00e7i HIV ilac\u0131n\u0131n \u00fcretilmesi ile devam etmesi \u00f6ng\u00f6r\u00fcl\u00fcyor.<\/p>\n
“3 y\u0131ld\u0131r \u00fczerinde \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z yerel \u00fcretim yat\u0131r\u0131m\u0131n\u0131 hayata ge\u00e7iriyoruz”<\/p>\n
Gilead Sciences T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc \u015eebnem Girgin, imza t\u00f6reninde yapt\u0131\u011f\u0131 konu\u015fmada, “Cumhurba\u015fkan\u0131 Erdo\u011fan\u2019\u0131n a\u00e7\u0131klad\u0131\u011f\u0131 100 G\u00fcnl\u00fck Eylem Plan\u0131 i\u00e7indeki \u00f6nemli maddelerden biri ila\u00e7 yerel \u00fcretimiydi. \u015eirket olarak bu konuyu 3 y\u0131l \u00f6nce politikalar\u0131m\u0131z i\u00e7ine alm\u0131\u015f ve \u00e7al\u0131\u015fmalara ba\u015flam\u0131\u015ft\u0131k. Bug\u00fcn de bu yat\u0131r\u0131m\u0131 hayata ge\u00e7irmekten gurur ve mutluluk duyuyoruz” dedi.<\/p>\n
Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131n\u0131n stratejik yerelle\u015fme hedefleri do\u011frultusunda, Pharmactive \u0130la\u00e7 ile \u00fcretim ve yat\u0131r\u0131m alan\u0131nda i\u015fbirli\u011fi anla\u015fmas\u0131n\u0131 imzalayan Girgin, bu imzayla birlikte \u015firketimizin halen geli\u015ftirmekte oldu\u011fu di\u011fer yenilik\u00e7i ila\u00e7lar\u0131n\u0131n da T\u00fcrkiye\u2019de \u00fcretilmesinin \u00f6n\u00fcn\u00fcn a\u00e7\u0131laca\u011f\u0131n\u0131 belirtti.<\/p>\n
Girgin, \u00fcretim ve yat\u0131r\u0131m projesine ili\u015fkin \u015fu bilgileri verdi: “Proje kapsam\u0131nda; \u015firketimizin portf\u00f6y\u00fcnde yer alan yenilik\u00e7i ve 2021\u2019e kadar patentli Hepatit B ve 2033\u2019e kadar patentli HIV tedavilerinin T\u00fcrkiye\u2019de \u00fcretilmesi i\u00e7in gereken teknoloji transferi faaliyetleri ba\u015fl\u0131yor. Bu proje ile T\u00fcrkiye, s\u00f6z konusu patentli ve yenilik\u00e7i Gilead ila\u00e7lar\u0131 i\u00e7in hali haz\u0131rda \u00fcretim yapmakta olan Kanada ve \u0130rlanda\u2019dan sonra d\u00fcnyadaki \u00fc\u00e7\u00fcnc\u00fc \u00fclke olacak ve \u015firketimizin T\u00fcrkiye toplam cirosunun y\u00fczde 70\u2019inden fazlas\u0131n\u0131 yerel olarak \u00fcretir duruma gelecek.Yine proje kapsam\u0131nda \u00f6n\u00fcm\u00fczdeki 4 y\u0131lda toplam 250 milyon dolarl\u0131k ithalat\u0131n \u00f6n\u00fcn\u00fcn kesilmesi m\u00fcmk\u00fcn g\u00f6r\u00fcn\u00fcyor. T\u00fcrkiye\u2019de \u00fcretim projemizin hayata ge\u00e7mesinin bir di\u011fer a\u00e7\u0131dan de\u011feri de, patentli ve d\u00fcnyada y\u00fcksek sat\u0131\u015f beklentisi olan bu ila\u00e7lar\u0131n ileriki d\u00f6nemlerde sahip oldu\u011fu ihracat potansiyelidir”.<\/p>\n
“\u00d6l\u00fcmc\u00fcl hastal\u0131klar\u0131n y\u00f6netilebilir hastal\u0131klara d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesine \u00f6nc\u00fcl\u00fck ediyoruz”<\/p>\n
\u015eirketin 32 y\u0131l \u00f6nce AIDS ve di\u011fer \u00e7aresi olmayan enfeksiyon hastal\u0131klar\u0131na \u00e7are bulabilmek amac\u0131 ile kurulmu\u015f bir bilim \u015firketi oldu\u011funu vurgulayan \u015eebnem Girgin, s\u00f6zlerine \u015f\u00f6yle devam etti: “\u015eirket olarak vizyonumuz ya\u015fam\u0131 tehdit eden hastal\u0131klara en iyi \u00e7\u00f6z\u00fcmleri geli\u015ftirerek bu hastal\u0131klar\u0131 yery\u00fcz\u00fcnden silmek. \u015eirket, bu ba\u011flamda HIV\/AIDS, Hepatit B, Hepatit C, hematoloji, onkoloji ve sistemik mantar enfeksiyonlar\u0131 gibi hastal\u0131klar\u0131n \u00f6l\u00fcmc\u00fcl olmaktan \u00e7\u0131k\u0131p, y\u00f6netilebilir hastal\u0131klara d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesi \u00e7abalar\u0131na \u00f6nc\u00fcl\u00fck etmi\u015ftir. D\u00fcnyan\u0131n ilk 10 ila\u00e7 firmas\u0131 aras\u0131nda yer alan \u015firketimiz, d\u00fcnya \u00e7ap\u0131nda y\u00fcr\u00fctt\u00fc\u011f\u00fc ara\u015ft\u0131rmalara y\u0131ll\u0131k yakla\u015f\u0131k 5 milyar dolar AR-GE kayna\u011f\u0131 ay\u0131rmakta, tedaviye eri\u015fim ve toplumsal e\u015fitsizlikleri yok etmek i\u00e7in d\u00fcnyada y\u0131ll\u0131k 400 milyon dolar ba\u011f\u0131\u015f yapmakta, k\u0131s\u0131tl\u0131 kaynaklara sahip \u00fclkelerde 12 milyon ki\u015fiye HIV tedavisi deste\u011fi sa\u011flamaktad\u0131r. T\u00fcrkiye\u2019de 2007 y\u0131l\u0131nda faaliyetlerine ba\u015flayan \u015firketimiz, 80\u2019in \u00fczerindeki \u00e7al\u0131\u015fan\u0131yla ya\u015fam\u0131 tehdit eden hastal\u0131klara y\u00f6nelik yenilik\u00e7i tedaviler sunmaktad\u0131r. T\u00fcrkiye\u2019de son 5 y\u0131lda 6 milyon dolar tutar\u0131nda AR-GE deste\u011fi sa\u011flam\u0131\u015f, Hayat Bulan Fikirler Bilimsel ve Sosyal Proje Destek Program\u0131 \u00e7er\u00e7evesinde 46 projeye toplam 700 bin dolar kar\u015f\u0131l\u0131ks\u0131z destek vermi\u015ftir. \u00d6zellikle bug\u00fcn burada imzalanacak anla\u015fma sonucu \u00fclkemizde \u00fcretim yap\u0131lacak olmas\u0131ndan dolay\u0131 onurluyuz”.<\/p>\n
Hayat kurtarmay\u0131 odaklar\u0131na ald\u0131klar\u0131n\u0131 belirten Girgin, patent s\u00fcreleri devam eden ve alanlar\u0131nda geli\u015ftirilmi\u015f en yenilik\u00e7i tedaviler sayesinde bir\u00e7ok bula\u015f\u0131c\u0131 hastal\u0131\u011f\u0131n kontrol alt\u0131na al\u0131nmas\u0131na katk\u0131 sa\u011flamaktan dolay\u0131 onur duyduklar\u0131n\u0131 ifade ederek s\u00f6zlerini \u015f\u00f6yle s\u00fcrd\u00fcrd\u00fc: “Hepatit B, \u015firket olarak uzun y\u0131llard\u0131r \u00fczerinde \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z ve etkin tedaviler geli\u015ftirdi\u011fimiz bir uzmanl\u0131k alan\u0131m\u0131zd\u0131r. Bug\u00fcn imza alt\u0131na ald\u0131\u011f\u0131m\u0131z yat\u0131r\u0131m karar\u0131m\u0131z ile birlikte \u00fclkemizde \u00fcretimine ba\u015flanacak olan ilk ila\u00e7, Hepatit B konusunda geli\u015ftirmi\u015f oldu\u011fumuz en son molek\u00fcld\u00fcr. \u015eirketin yenilik\u00e7i ila\u00e7 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131n\u0131n aral\u0131ks\u0131z s\u00fcrd\u00fc\u011f\u00fc bir di\u011fer alan olan HIV\/AIDS konusu da \u00fclkemizdeki sa\u011fl\u0131k sistemi i\u00e7inde etkin bir \u015fekilde y\u00f6netilmektedir. 1996 y\u0131l\u0131nda kurulan Ulusal AIDS komisyonu ve halihaz\u0131rda geli\u015ftirme a\u015famas\u0131nda olan Ulusal HIV\/AIDS Program\u0131, bakanl\u0131\u011f\u0131m\u0131z\u0131n bu hastal\u0131klara verdi\u011fi \u00f6nemi ve kontrol\u00fc i\u00e7in uluslararas\u0131 standartlarda y\u00fcr\u00fctt\u00fc\u011f\u00fc \u00e7al\u0131\u015fmalar\u0131 vurgulamaktad\u0131r. Bu ba\u011flamda \u00fclkemizde \u00fcretilecek ikinci Gilead ilac\u0131 da HIV alan\u0131ndaki en son ke\u015ffedilen molek\u00fcl\u00fc i\u00e7eren ila\u00e7 olacakt\u0131r. T\u00fcm bunlara ek olarak, D\u00fcnyadaki eliminasyon \u00e7abalar\u0131na \u00f6nc\u00fcl\u00fck etti\u011fimiz Hepatit C alan\u0131nda da DS\u00d6 2030 hedeflerine ula\u015f\u0131lmak \u00fczere bakanl\u0131\u011f\u0131m\u0131z taraf\u0131ndan y\u00fcr\u00fct\u00fclen t\u00fcm \u00e7al\u0131\u015fmalar\u0131 yak\u0131ndan takip ediyor, taraf\u0131m\u0131za d\u00fc\u015fen t\u00fcm g\u00f6revlere de haz\u0131r oldu\u011fumuzun bilinmesini istiyoruz”.<\/p>\n
“Uluslararas\u0131 standartlarda biyoteknolojik ila\u00e7 \u00fcretebilecek say\u0131l\u0131 \u00fclkelerden biriyiz”<\/p>\n
Pharmactive \u0130la\u00e7 Y\u00f6netim Kurulu Ba\u015fkan\u0131 Haluk Sancak da, 2011 y\u0131l\u0131nda Saya Grup b\u00fcnyesinde \u015firketi kurarken, \u00fcretim kapasitesinin ve yetkinli\u011finin y\u00fcksek olmas\u0131n\u0131 planlad\u0131klar\u0131n\u0131 belirterek, “Fabrikam\u0131z\u0131n 330 milyon kutuluk kapasitesi, \u00fclkemiz ve hatta Avrupa\u2019n\u0131n tamam\u0131nda hat\u0131r\u0131 say\u0131l\u0131r bir seviyededir. \u015eirket olarak, 860 ki\u015fiye istihdam sa\u011flamaktay\u0131z. 8 y\u0131lda tamam\u0131 kendi laboratuvarlar\u0131m\u0131zda olmak \u00fczere 90 e\u015fde\u011fer molek\u00fcl geli\u015ftirdik. \u015eu anda \u00fclkemizde en \u00e7ok \u00fcretim yapan ilk 5 tesisten biri durumunday\u0131z. Halihaz\u0131rda \u00fcretimimizin yar\u0131s\u0131n\u0131 \u00e7ok uluslu \u015firketler i\u00e7in yapmaktay\u0131z” dedi.<\/p>\n
T\u00fcrkiye\u2019nin bug\u00fcne kadar olu\u015fturulmu\u015f olan ila\u00e7 \u00fcretim k\u00fclt\u00fcr\u00fc ve motivasyonu sayesinde her ilac\u0131 \u00fcretebilir durumda oldu\u011funu s\u00f6yleyen Haluk Sancak, biyoteknolojik ila\u00e7 \u00fcretimi konusunda \u00e7al\u0131\u015fmalar\u0131n\u0131n s\u00fcrd\u00fc\u011f\u00fcn\u00fc belirtti. Sancak, s\u00f6zlerini \u015f\u00f6yle tamamlad\u0131: “Bizler T\u00fcrkiye\u2019nin bir \u00fcretim \u00fcss\u00fc haline gelece\u011fine y\u00fcrekten inan\u0131yoruz. \u00dclkemizin d\u00fcnya i\u00e7in ila\u00e7 \u00fcreten bir \u00fcs haline gelmesi i\u00e7in \u015firket olarak \u00fczerimize d\u00fc\u015feni yapmaya her zaman devam edece\u011fiz. Molek\u00fcl ke\u015ffinde son zamanlar\u0131n en \u00e7ok dikkat \u00e7eken ba\u015far\u0131lar\u0131n\u0131 elde etmi\u015f bilim \u015firketi Gilead Sciences ile iki y\u0131l \u00f6nce ilk g\u00f6r\u00fc\u015fmeyi yapm\u0131\u015ft\u0131k. ABD\u2019den gelen \u015firket yetkilileri, tesisimizi ziyaretlerinin ard\u0131ndan, \u2019\u2019T\u00fcrkiye\u2019de b\u00f6yle bir tesis olabilece\u011fini gelmeden \u00f6nce bilmiyorduk\u2019\u2019 \u015feklinde geri bildirimlerde bulundular. Pharmactive\u2019i, Gilead\u2019\u0131n globaldeki ihtiya\u00e7lar\u0131n\u0131 kar\u015f\u0131layacak tesislerden birisi olarak g\u00f6rd\u00fcklerini ifade ettiler. Bu geri bildirimler i\u015fbirli\u011fimizin \u00f6n\u00fcn\u00fcn \u00e7ok a\u00e7\u0131k oldu\u011funu g\u00f6stermektedir. ABD\u2019li \u015firket ile yapaca\u011f\u0131m\u0131z i\u015fbirli\u011fi \u00fclkemiz ekonomisine de b\u00fcy\u00fck katk\u0131lar sa\u011flayacakt\u0131r. Bu i\u015fbirli\u011finin sekt\u00f6rdeki di\u011fer yabanc\u0131 yat\u0131r\u0131mlar\u0131n da \u00f6n\u00fcn\u00fc a\u00e7aca\u011f\u0131na y\u00fcrekten inan\u0131yorum. \u0130mzalanan i\u015fbirli\u011fi anla\u015fmas\u0131 ayn\u0131 zamanda yabanc\u0131 yat\u0131r\u0131mc\u0131lara verilen bir g\u00fcven mesaj\u0131d\u0131r, bu nedenle de \u00fclke ekonomisi i\u00e7in olduk\u00e7a \u00f6nemlidir. Bizler \u00fclkemizin s\u00fcrd\u00fcr\u00fclebilir sa\u011fl\u0131\u011f\u0131 i\u00e7in adanm\u0131\u015fl\u0131kla \u00e7al\u0131\u015fan g\u00fc\u00e7l\u00fc bir ekibiz. \u00dcst\u00fcm\u00fcze d\u00fc\u015fenin her zaman daha fazlas\u0131n\u0131 da yapmaya haz\u0131r\u0131z”.<\/p>\n","protected":false},"excerpt":{"rendered":"
PHARMACT\u0130VE \u0130LA\u00c7 Y\u00d6NET\u0130M KURULU BA\u015eKANI HALUK SANCAK DA, 2011 YILINDA SAYA GRUP B\u00dcNYES\u0130NDE \u015e\u0130RKET\u0130 KURARKEN, \u00dcRET\u0130M KAPAS\u0130TES\u0130N\u0130N VE YETK\u0130NL\u0130\u011e\u0130N\u0130N Y\u00dcKSEK OLMASINI PLANLADIKLARINI BEL\u0130RTEREK, “FABR\u0130KAMIZIN 330 M\u0130LYON KUTULUK KAPAS\u0130TES\u0130, \u00dcLKEM\u0130Z VE HATTA AVRUPA\u2019NIN TAMAMINDA HATIRI SAYILIR B\u0130R SEV\u0130YEDED\u0130R. \u015e\u0130RKET OLARAK, 860 K\u0130\u015e\u0130YE \u0130ST\u0130HDAM SA\u011eLAMAKTAYIZ. 8 YILDA TAMAMI KEND\u0130 LABORATUVARLARIMIZDA OLMAK \u00dcZERE 90 E\u015eDE\u011eER MOLEK\u00dcL GEL\u0130\u015eT\u0130RD\u0130K. \u015eU ANDA \u00dcLKEM\u0130ZDE EN \u00c7OK \u00dcRET\u0130M YAPAN \u0130LK 5 TES\u0130STEN B\u0130R\u0130 DURUMUNDAYIZ. HAL\u0130HAZIRDA \u00dcRET\u0130M\u0130M\u0130Z\u0130N YARISINI \u00c7OK ULUSLU \u015e\u0130RKETLER \u0130\u00c7\u0130N YAPMAKTAYIZ” DED\u0130.<\/p>\n","protected":false},"author":1,"featured_media":164042,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[19],"tags":[5736,3712,8555,4071,470],"class_list":["post-164041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ekonomi","tag-abdli","tag-ilac","tag-sirketinden","tag-turkiyeye","tag-yatirim"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.tvturk.com\/wp-content\/uploads\/2019\/05\/abdli-ilac-sirketinden-turkiyeye-yatirim_f895fb9.jpg?fit=1000%2C904","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/paKIfm-GFP","_links":{"self":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts\/164041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/comments?post=164041"}],"version-history":[{"count":0,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts\/164041\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/media\/164042"}],"wp:attachment":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/media?parent=164041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/categories?post=164041"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/tags?post=164041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}